Tao Capital Management LP lowered its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 97.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,683 shares of the company's stock after selling 221,671 shares during the period. Ginkgo Bioworks comprises about 0.0% of Tao Capital Management LP's portfolio, making the stock its 10th biggest position. Tao Capital Management LP's holdings in Ginkgo Bioworks were worth $46,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Paloma Partners Management Co acquired a new position in shares of Ginkgo Bioworks in the first quarter worth approximately $28,000. Algert Global LLC acquired a new stake in shares of Ginkgo Bioworks during the second quarter worth $36,000. Russell Investments Group Ltd. raised its stake in Ginkgo Bioworks by 9,440.6% during the first quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company's stock worth $37,000 after buying an additional 31,626 shares during the last quarter. Wellington Wealth Strategies LLC. acquired a new position in Ginkgo Bioworks in the second quarter valued at $41,000. Finally, Thoroughbred Financial Services LLC bought a new stake in Ginkgo Bioworks during the second quarter valued at $70,000. Institutional investors and hedge funds own 78.63% of the company's stock.
Ginkgo Bioworks Price Performance
Shares of NYSE DNA traded down $0.10 during trading on Wednesday, hitting $6.35. 465,408 shares of the company traded hands, compared to its average volume of 1,149,782. The firm has a market cap of $352.90 million, a price-to-earnings ratio of -0.49 and a beta of 1.09. The firm has a fifty day moving average of $7.81. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $75.20.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on DNA shares. BTIG Research lifted their price objective on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research report on Friday, August 23rd. TD Cowen lifted their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Hold" and an average price target of $4.58.
Check Out Our Latest Stock Report on DNA
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
